I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Italy

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ESMO 2024
Roche and Genentech at

ESMO 2024

September 13 - September 17
Barcelona, Spain
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
02:10 PM
Duration 10mins Sevilla Auditorium - Hall 2
Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
Yopp A, Chen M, Cheng A, Kaseb A, Kudo M, Lee HC, Cha E, Hack S, Lian Q, Spahn J, Wu C, Shukui Q
Oncology | Liver Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:00 AM
Duration 8hrs Barcelona, Spain
Phase I Study of SOF10 Plus Atezolizumab in Patients with Advanced/Recurrent Solid Tumours
Toshihiko Doi, Yasutoshi Kuboki, Shigehiro Koganemaru, Takafumi Koyama, Jun Sato, Yuki Katsuya, Eisuke Ueda, Kei Higashikawa, Takaaki Ishida, Mikiko Nakamura, Shizuka Nakagawa, Noboru Yamamoto
Solid Tumours | Oncology

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:00 AM
Duration 8hrs Barcelona, Spain
Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Dziadziuszko R, Damian S, Gadgeel S, Garralda E, Italiano A, Kim JE, Krzakowsi M, Lin C-C, Popovtzer A, Thomas D, Kirschbrown W, Patel S, Pham T, Sbirnac M, Wu F, Barlesi F
Oncology | Tumor Agnostic Biomarker Positive Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8hrs Barcelona, Spain
IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 tumour cell (TC) >=50% NSCLC who were disease free at 5 years (5yDF) in a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)
Enriqueta Felip, Eric Vallières, Olexandr Golobordko, Alex Martinez Marti, Caicun Zhou, Achim Rittmeyer, Antonio Chella, Martin Reck, Roman Vereshchako, Wolfgang Schütte, Morihito Okada, Rüdiger Liersch, Encarnação Teixeira, Heather Wakelee, Lisa Bennett, Barbara Gitlitz, Marcus Ballinger, Cindy Zhu, Leonardo Crama
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8hrs Barcelona, Spain
Updated efficacy and safety of entrectinib▼ in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC
Matthew G. Krebs, Shun Lu, Yun Fan, Yan Yu, Alexander Drilon, Salvatore Siena, Cloris Xue, Denise Bradley, Xichun Hu
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8hrs Barcelona, Spain
IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Heather Wakelee, Martin Reck, Enriqueta Felip, Nasser Altorki, Eric Vallieres, Rüdiger Liersch, Satoshi Oizumi, Hiroshi Tanaka, John T. Hamm, Steven McCune, Elizabeth Bennett, Barbara J Gitlitz, Virginia McNally, Silvia Novello, Marcus Ballinger, Wei Zou, Barzin Y. Nabet, Minu K. Srivastava, Caicun Zhou
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 1hr Barcelona, Spain
Second OS interim analysis from BEAT-SC: A randomized Phase III study of bevacizumab (bev) or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)
Baohui Han, Yuichiro Ohe, Makoto Nishio, Satoshi Watanabe, Xiubao Ren, Shuji Murakami, Nong Yang, Isamu Okamoto, Gaofeng Li, Nobuyuki Katakami, Xianling Liu, Naohiko Hamaguchi, Yuki Nakagawa, Morihiko Hayashi, Toshihiro Nanki, Chunyu Qian, Nobuyuki Yamamoto
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:45 PM
Duration 90mins Oviedo Auditorium - Hall 3
Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors
Elena Garralda, Manish R. Patel, Tae Won Kim, Adrian Sacher, Martin Forster, Armando Santoro, Jayesh Desai, Luis Paz-Ares, Alejandro Falcon, Maria de Miguel, Samantha Bowyer, Rafal Dziadziuszko, Se Hyun Kim, Sae-Won Han, Matthew G. Krebs, Patricia LoRusso, Rasha Cosman, Julie Chang, Tomi Jun, Wilson H. Miller Jr.
Oncology | Colorectal Cancer - Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 AM
Duration 8hrs Barcelona, Spain
Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)
Perez Valderrama B, Garcia del Muro X, Merseburger AS, Loriot Y, Choy E, Castellano D, Lopez-Rios F, Bonfill T, Montesa A, Yu P, Skamnioti P, Sternberg CN
Oncology | Urinary Bladder Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:00 AM
Duration 8hrs Barcelona, Spain
Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
Bochtler T, Kramer A, Pauli C, Duran-Pacheco G, Arslan C, Bigot F, Chalabi N, Cook N, Italiano A, Losa F, Janoski de Menezes J, Ma N, Ozguroglu M, Pazo-Cid R.A, Ross J.S, Shiu K.K, Arni P, Moch H, Mileshkin L
Oncology | Carcinoma of Unknown Primary

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8hrs Barcelona, Spain
Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry
Le Tourneau C, Dienstmann R, Hackshaw A, Geissler J, Ferro A, Cheese E, Schirghuber E, Blay J-Y
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 1hr Barcelona, Spain
Patient matters: Innovation in lung cancer
Benjamin J Solomon, Fernando Lopez-Rios, Jarushka Naidoo, Margarita Majem
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:00 AM
Duration 8hrs Barcelona, Spain
Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS Breast Cancer (BC): A Phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Oliveira M, Gion M, Jung H, Bermejo M, Hurvitz S, Sadeghi S, Wander S, Seock I, Gal-yam E, Zhu J, Schwab R, Ngo H, Collier A, Cannon M, Cahuzac C, Pablo P, McIntosh S, Saavedra C, Sonnenblick A.
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 1hr Barcelona, Spain
How can we PI3K the right treatment for every patient with HR+ breast cancer?
Carlos Barrios; Komal Jhaveri, Kevin Kalinsky
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:50 PM
Duration 5mins Sevilla Auditorium - Hall 2
ALINA: exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
Solomon BJ, Wu Y-L, Dziadziuszko R, Barlesi F, Nishio M, Ahn J-S, Horinouchi H, Hochmair M, de Marinis F, Migliorino MR, Kurochkin A, Harputluoglu H, Planchard D, Korphaisarn K, Han J-Y, Ochi Lohmann T, Cardona A, Archer V, Nowicka M, Noe J
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:55 PM
Duration 10mins Madrid Auditorium - Hall 2
Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity
Thorball CW, Quandt Z, Saha A, Yao L, Middha P, Xu Y, Bejan CA, Hodel F, Stravodimou A, Shearer-King ES, Aldrich M, Phillips EJ, Liu G, Schoenfeld A, Johnson DB, Ziv E, Fellay J, Mohindra R, Balko J, Chandler GS
Oncology | Pan-tumour

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 90mins Barcelona, Spain
Roche Symposium at ESMO: Pioneering GI Cancer Treatments and Maximising Outcomes for Patients with HCC (slides)
Richard Finn
Oncology | Liver Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.